시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 VI 다당류 장티푸스 백신 시장 보고서(2025년)
Typhoid Vi Polysaccharide Vaccine Global Market Report 2025
상품코드 : 1821654
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

VI 다당류 장티푸스 백신 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년 연평균 성장률(CAGR)은 18.2%로 130억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 예방접종 프로그램 확대, 세계 보건 정책의 중요성, 역학 감시, 여행 의학에 대한 수요 증가, 환경 및 사회적 요인에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 연구개발 투자, 규제 지원, 역학 조사, 공중보건 인식 등이 있습니다.

향후 5년간 18.2%의 성장률 전망은 지난번 예측보다 0.4% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 인도와 벨기에에서 개발된 장티푸스 결합형 백신의 가격이 치솟아 백신 접종률 하락과 공중보건 비용 상승을 초래하여 미국의 예방접종 프로그램 도입에 장애가 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

장티푸스 유행 증가는 향후 VI 다당류 장티푸스 백신 시장의 성장을 견인할 것으로 예상됩니다. 장티푸스는 살모넬라균(Salmonella typhi)에 의해 발생하는 감염성 질환으로 생명을 위협할 수 있으며, 보통 오염된 음식물을 통해 감염됩니다. VI 다당질 장티푸스 백신은 장티푸스균(S.Typhi)에 의한 장티푸스를 예방하기 위해 성인과 2세 이상의 소아에게 접종하는 백신입니다. 예를 들어, 영국 정부 기관인 UK Health Security Agency가 2024년 8월에 발표한 데이터에 따르면, 영국, 웨일즈, 북아일랜드의 장티푸스 실험실 확진 사례는 2021년부터 2022년까지 증가했으며, S. Typhi는 108건에서 313건으로, S. Paratyphi A는 31건에서 135건으로, S. Paratyphi B는 13건에서 18건으로 증가했습니다. 그 결과, 장티푸스 유병률의 증가는 VI 다당류 장티푸스 백신 시장의 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

The Typhoid Vi polysaccharide vaccine is recommended for active immunization in individuals aged two and older to prevent typhoid fever caused by Salmonella typhi.

The primary variants of this vaccine are tailored for pediatric and adult use. A child denotes an individual from birth to puberty or reaching full physical maturity. The vaccine can be administered orally or through parenteral routes and is accessible across governmental, private, and other institutional healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The typhoid Vi polysaccharide vaccine market research report is one of a series of new reports from The Business Research Company that provides typhoid Vi polysaccharide vaccine market statistics, including typhoid Vi polysaccharide vaccine industry global market size, regional shares, competitors with typhoid Vi polysaccharide vaccine market share, detailed typhoid Vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in typhoid Vi polysaccharide vaccine industry. This Typhoid Vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $5.78 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $13.09 billion in 2029 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors. Major trends in the forecast period include R&D investments, regulatory support, epidemiological studies, public health awareness.

The forecast of 18.2% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of preventive immunization programs by inflating prices of typhoid conjugate vaccines developed in India and Belgium, resulting in lower vaccination rates and higher public health costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of typhoid is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Typhoid is an infection caused by the bacteria Salmonella typhi, which can be life-threatening and is typically spread through contaminated food or drink. The Typhoid Vi polysaccharide vaccine is administered to immunize both adults and children aged two and older against typhoid fever caused by Salmonella enterica serovar Typhi (S. Typhi). For example, in August 2024, data published by the UK Health Security Agency, a government agency in the UK, revealed that laboratory-confirmed symptomatic cases of enteric fever in England, Wales, and Northern Ireland rose from 2021 to 2022, with cases of S. Typhi increasing from 108 to 313, S. Paratyphi A from 31 to 135, and S. Paratyphi B from 13 to 18. Consequently, the rising prevalence of typhoid is fueling the growth of the typhoid VI polysaccharide vaccine market.

The expansion of immunization campaigns is expected to drive the growth of the typhoid VI polysaccharide vaccine market in the coming years. Immunization campaigns are strategies designed to rapidly deliver one or more vaccines to large populations, typically organized at the national or sub-national level. These campaigns are crucial for the effective distribution and use of the typhoid VI polysaccharide vaccine, particularly in areas where typhoid fever presents a significant public health issue. For example, in April 2022, the Government of Nepal, with support from Gavi, the Vaccine Alliance-a public-private global health partnership-the World Health Organization (WHO), a Switzerland-based intergovernmental organization, and the United Nations International Children's Emergency Fund (UNICEF), a US-based humanitarian aid organization, launched a new vaccination campaign to incorporate the Typhoid Conjugate Vaccine (TCV) into the country's routine immunization program. This three-week campaign, running from April 8 to May 1, 2022, aims to vaccinate all children aged 15 months to 15 years to quickly enhance protection against typhoid, maximize the impact of the vaccine introduction, and address the growing issue of antimicrobial resistance. More than 50,000 vaccination sites have been set up across both rural and urban areas of the country, including schools. Thus, the increasing number of immunization campaigns is driving the growth of the typhoid VI polysaccharide vaccine market.

Increasing expenditure in the healthcare sector is anticipated to drive the growth of the typhoid VI polysaccharide vaccine market in the future. Healthcare expenditure encompasses the total costs associated with healthcare, including both public and private spending, as a percentage of GDP. Higher healthcare expenditure enables manufacturers of the typhoid VI polysaccharide vaccine to develop additional vaccines, thereby boosting demand in the market. For example, in September 2024, statistics released by Cross River Therapy, a US-based provider of ABA therapy services, indicated that the U.S. pharmaceutical industry generated $550 billion in revenue. Americans spent $576.9 billion on medications in 2021, with projected spending expected to rise to between $605 billion and $635 billion by 2025. Thus, the increasing expenditure in the healthcare sector is fueling the growth of the typhoid VI polysaccharide vaccine market.

Strategic partnerships are emerging as a significant trend in the typhoid VI polysaccharide vaccine market. Key players in this market are forming alliances to enhance their positions within the typhoid VI polysaccharide sector. For example, in July 2022, the International Vaccine Institute, an organization based in South Korea that focuses on infectious diseases of global health significance such as cholera, typhoid, shigella, and salmonella, collaborated with Moderna, a US-based biopharmaceutical firm. This partnership resulted in the development of the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Key companies in the typhoid VI polysaccharide vaccine market are prioritizing investments to maintain their competitive edge. Significant investments in the development and distribution of the typhoid VI polysaccharide vaccine highlight the critical importance of preventing and controlling typhoid fever. For instance, in August 2023, SK Bioscience, a South Korean biotech firm, and Vaxxas, an Australian biotechnology company specializing in a novel needle-free vaccination technology, secured AUD5.4 million (approximately $3.67 million) in funding from Wellcome, a UK-based charity. This funding aims to develop a typhoid conjugate vaccine that can be administered through a needle-free patch. This collaboration seeks to transform vaccine delivery by creating an innovative vaccine-delivery device that combines Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK Bioscience's proprietary typhoid vaccine.

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2024. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Typhoid Vi Polysaccharide Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on typhoid vi polysaccharide vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for typhoid vi polysaccharide vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The typhoid vi polysaccharide vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Typhoid Vi Polysaccharide Vaccine Market Characteristics

3. Typhoid Vi Polysaccharide Vaccine Market Trends And Strategies

4. Typhoid Vi Polysaccharide Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Typhoid Vi Polysaccharide Vaccine Growth Analysis And Strategic Analysis Framework

6. Typhoid Vi Polysaccharide Vaccine Market Segmentation

7. Typhoid Vi Polysaccharide Vaccine Market Regional And Country Analysis

8. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market

9. China Typhoid Vi Polysaccharide Vaccine Market

10. India Typhoid Vi Polysaccharide Vaccine Market

11. Japan Typhoid Vi Polysaccharide Vaccine Market

12. Australia Typhoid Vi Polysaccharide Vaccine Market

13. Indonesia Typhoid Vi Polysaccharide Vaccine Market

14. South Korea Typhoid Vi Polysaccharide Vaccine Market

15. Western Europe Typhoid Vi Polysaccharide Vaccine Market

16. UK Typhoid Vi Polysaccharide Vaccine Market

17. Germany Typhoid Vi Polysaccharide Vaccine Market

18. France Typhoid Vi Polysaccharide Vaccine Market

19. Italy Typhoid Vi Polysaccharide Vaccine Market

20. Spain Typhoid Vi Polysaccharide Vaccine Market

21. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market

22. Russia Typhoid Vi Polysaccharide Vaccine Market

23. North America Typhoid Vi Polysaccharide Vaccine Market

24. USA Typhoid Vi Polysaccharide Vaccine Market

25. Canada Typhoid Vi Polysaccharide Vaccine Market

26. South America Typhoid Vi Polysaccharide Vaccine Market

27. Brazil Typhoid Vi Polysaccharide Vaccine Market

28. Middle East Typhoid Vi Polysaccharide Vaccine Market

29. Africa Typhoid Vi Polysaccharide Vaccine Market

30. Typhoid Vi Polysaccharide Vaccine Market Competitive Landscape And Company Profiles

31. Typhoid Vi Polysaccharide Vaccine Market Other Major And Innovative Companies

32. Global Typhoid Vi Polysaccharide Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Typhoid Vi Polysaccharide Vaccine Market

34. Recent Developments In The Typhoid Vi Polysaccharide Vaccine Market

35. Typhoid Vi Polysaccharide Vaccine Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기